LYCOPENE EFFICACY TOWARDS STREPTOZOTOCIN INDUCE COGNITIVE DYSFUNCTION: A PRELIMINARY POSSIBLE FUTURE ALTERNATIVE FOR NEUROLOGICAL AILMENTS

Mohammad Yusuf
Department of Clinical Pharmacy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.

Abstract

Lycopene, a red-colored carotenoid, established for its antioxidant potentials towards cognitive dysfunction, a predictor of neurological maladies. Plentiful research in arena emphasizing towards formulation advancement and dose adjustment, inclining to impart an edge for lycopene biopotentials, but still leaving a lag. Current preliminary research emphasizes on therapeutic potentials of lycopene over cognitive dysfunction at certain doses established via behavioral models. Lycopene 100mg/kg dose depicted a significant immobility time curtail to 53.33±4.356secs in despair Test (DT), 25.67±2.028 crossing in Light and dark (LD) simulation, and 22.67±1.116 rotations in manual rota-wheels(RW) design respectively, in contrast to STZ control 83.50±4.766 sec (DT), 14.67±1.764 (RD) and 9.333±1.606(RW) respectively. Lycopene 100 mg/kg dose depicted positive and impressive results against cognitive dysfunction. Prospectively, Lycopene could be utilized as an alternative supplement for neurological diseases.

Introduction:

Lycopene, a red-colored carotenoid recognized for antioxidant potentials. Being an effective radical scavenger, it owes for various neurological activities. Cognitive dysfunction is a designated predictor of any neurological disease[1]. Several studies conducted where cognitive dysfunction was evaluated to correlate depression, Epilepsy, Alzheimer’s, Parkinson’s, and other neurological ailments[2-5]. Oxidative-stress (OS), a designated source of neurological diseases instigated by endogenic antioxidant system accompanied by cognitive dysfunction. OS generated ROS oxidizes brain macro-molecules and reported a trigger of cognitive abnormalities. Lycopene adopts several antioxidant mechanisms to decrease oxidative stress but due to diminished bioavailability, it fails to express its potential[2-5]. Although Lycopene shown a lipophilic characteristic due to conjugated system, but its high molecular weight (C_{40}H_{56}=536.87 g/mol) limits its bioavailability. Geometrical isomerism influences its bioavailability as cis-isomers impart thermal stability and higher absorption rate in humans [6, 7]. Lycopene absorption also varied with age and diet type, affecting its bioavailability[8][9]with a half-life of 2-3 days[10]. Besides liver it accumulates in adipose tissues, kidneys, lungs, and other lipid-containing organs[6, 7]. Several toxicity studies suggested appropriate dose of 5-10 mg/kg, but no toxic effects noticed in rats administered 3 g/kg/day [11]. Cognitive dysfunction is a designated hallmark of diabetic patient hence artificial diabetes develops in rats via streptozotocin (STZ) to gain cognitive model[12]. STZ acts by activating GTS and further favoring superoxide radicals (O_{2}^{'}) generation (Figure 1). Plentiful research is still in arena emphasizing formulation
development and dose adjustment to impart an edge for lycopene bio-potentials, but still leaving a lag. Current preliminary research emphasizes on therapeutic potentials of lycopene over cognitive dysfunction at certain doses established via behavioral models.

**Materials and Methods:**

**Materials:**
Streptozotocin, Lycopene, Hamilton micro-syringe, 27G needle, citrate buffer, distilled Water procured from Sigma Aldrich, USA, mice food pellet was obtained from local distributor.

**Invivo Experiment:**
Six groups of 6 albino mice were approved by the institutional ethical committee. Albino mice (20 to 25 gm) were domesticated as standard guidelines (25°C, light, and dark diurnal 12/12 hrs cycle, appropriate food and water)[13].

**Streptozotocin (STZ) engendered Cognitive dysfunction (SCD)[14]:**
STZ administered in mice via anesthetizing by isoflurane through i.c.v. route by 27G needle, 25 μl Hamilton micro-syringe interleaved perpendicular (2 mm) through skull in particular coordinates (Figure 1). STZ-Controlled group delivered STZ i.c.v.(0.1 mg/site, 4 μl citrate buffer) at 1 and 48 hrs to gain Cognitive dysfunction[15].

**Dosing:**
SCD encompassed 6 groups of 6 animals (already STZ engendered), received lycopene in 0, 10, 50, 100, 150, 200 mg/kg dose via intraperitoneal route in tween-80 suspension. Cognitive activity was measured via Despair test, manual rota-wheel, and Light and dark simulation, 45 minutes post-drug administration. Readings were taken individually and back-to-back switching from one to another model.

**Despair Test (DT):**
Animals were forcefully made swim (15 minutes) in Water-filled (Ht=10 cm) Plexiglass cylinder (Ht=25, Dia=10 cm) at 25°C. Total immobility duration (no struggling and float motionless) was gauged during 15 mins[16].

**Light and dark simulation (RD):**
Animal cage (44x21x21 cm) was darkened 1/3rd black (spray paint), 1/3rd, and other 1/3rd was kept in bright LED. Number of crossing from dark to light and vice versa was evaluated in 15 minutes.

**Manual Rota-wheel Design (RW):**
Animals could rotate wheel, diameter15 cm and thickness 4cm, rotating at their free will, rotations number were assessed in 10 minutes.

**Statistical Assessment:**
Statistical assessment was handled via one-way analysis of variance (ANOVA) pursued through Dunnett’s test. P<0.05, deemed designated as statistically significant, using Graphpad (V9, LLC, USA)

**Result and Discussion:**
Lycopene a red, structurally open-chain isomer of β-carotene comprising conjugated (11) and unconjugated (2) double bonds system which imparts a tremendous antioxidant activity towards OS. OS contributes to development of several chronic neurological ailments. Antioxidants act by scavenging free radicals or reactive-oxygen species (ROS), relieving neurodegeneration. Brain often requires consistent oxygen supply and possibly culprit to ROS generation during fail response of intrinsic anti-oxidation system, heading to OS. Intrinsic antioxidant system failure implies improper ROS generation and counteraction[17,18]. Intrinsic oxidases are liable for superoxide radical production, further metabolized to H$_2$O$_2$ and water by other oxidases and peroxidases[19-22]. STZ actuates neuron’s glutamatergic-Transmitter for generation of ROS (Figure-1)[21, 23].

Lycopene scavenges singlet and excited oxygen species and also acts by restoring the functioning of antioxidant enzymes[24], reducing oxidative damage to DNA and biomolecules[25]. Several studies confirmed the safe doses of lycopene as 75 mg/day or ranging 10-120 mg/day. Intake spans prescribed from country to country as 3.7-16.15 mg United States, Germany 0.7-1.3 mg, Canada of 25.2 mg etc.[27], DT, LD simulation, and RW design are perfect.
models for Cognitive assessment. DT assess brain alertness reflects by immobility, cognition impairment, accomplishing fast results with high validity and reliability.

Table 1:-Lycopene dose 0, 10, 50, 100, 150, 200 mg/kg evaluation. Results expressed in Mean±SEM, Significance represented as p<****0.0001, ***0.001, **0.01, *0.05) contrasted to control group via ANOVA post Dunnett’s test.

| Group No. | Treatment          | DT     | LD simulation (no of crossing) | RW Design (No of rotations) |
|-----------|--------------------|--------|--------------------------------|-----------------------------|
| 1         | STZ control        | 83.50±4.766 | 14.67±1.764 | 9.333±1.606 |
| 2         | STZ+10 mg/kg Lyc   | 69.83±5.009 | 14.33±1.606 | 9.833±1.470 |
| 3         | STZ+50 mg/kg Lyc   | 64.33±4.240* | 22.67±1.944* | 15.50±1.478**** |
| 4         | STZ+100 mg/kg Lyc  | 55.67±2.362** | 25.67±2.028*** | 22.67±1.116** |
| 5         | STZ+150 mg/kg Lyc  | 53.33±4.356*** | 19.67±1.820 | 19.33±3.138*** |
| 6         | STZ+200 mg/kg Lyc  | 51.83±6.431*** | 20.00±1.211 | 22.50±1.607 |

Figure 1:-Oxidative stress Series: A. streptozotocin mechanism in OS development, B. Lycopene ROS scavenging mechanism against OS engendered Cognitive dysfunction

Lycopene dose at 100, 150, and 200 mg/kg predicted a significant immobility time decrement of 55.67±2.362, 53.33±4.356, 51.83±6.431 secs respectively, contrasting with STZ control (83.50±4.766 sec) (Figure-2, Table-1). LD simulation established on light and dark environment exploration. Neuroactive drugs increase crossing number between dark and light compartments. LD simulation often uses to gauge learning, anxiety, and exploration, rodents. LD also employed to test impulsivity, neural systems relevancy. Number of crossing from light to dark or contrariwise for 10 minutes counted as parameter[28]. Lycopene dose at 50 and 100 mg/kg showed a significant crossing number of 22.67±1.944, and 25.67±2.028 respectively, contrasting with STZ control (14.67±1.764) (Figure-2, Table-1). RW functions like LD simulation, mostly neuroactive drugs increase rotation numbers. Lycopene dose (mg/kg) at 100, 150 and 200 predicted significant rotation number of 15.50±1.478, 22.67±1.116, and 19.33±3.138 respectively contrasting with STZ control (9.333±1.606) (Figure-2, Table-1). Overall representation proved Lycopene as a neuroactive drug. 10 mg/kg dose didn’t show appropriate response, whereas 50 had shown some but dose (mg/kg)100, 150 and 200 demonstrated a significant result but as almost close responses. Safe dose range of lycopene reported 10-120 mg/kg, thus we conclude 100 mg/kg dose of lycopene as effective against cognitive dysfunction.
Figure 2 A:-Despair test, (parameter: immobility time in seconds/5 minutes), B. Light and dark simulation, (Parameter: crossing number/10 minutes), C. Manual rota-wheel design (Parameter: number of rotation/10 minutes). Results expressed in Mean±SEM. Significance represented as p<****0.0001,***0.001,**0.01,*0.05) contrasted to control group via ANOVA post-Dunnett’s test.

Conclusion:--
Lycopene 100 mg/kg dose depicted positive and impressive results in cognitive dysfunction. Lycopene proposed on acting over Oxidative cascade, intrinsic oxidases, and peroxidases. Like other polyene antioxidants like curcumin, Carotenoids, and piperine, lycopene might also share similar neuroactivity. Lycopene can be employed as an alternative supplement for neurological diseases.

Disclosure:-
Author states of no conflict of interest.

Acknowledgement:-
Author expresses immense gratitude to College of Pharmacy for providing Research facilities.

References:-
1. M. Yusuf, M. Khan, M.A. Robaian, R.A. Khan, Biomechanistic insights into the roles of oxidative stress in generating complex neurological disorders, Biological chemistry, 399 (2018) 305-319.
2. M. Yusuf, M. Khan, M.M. Alrobaian, S.A. Alghamdi, M.H. Warsi, S. Sultana, R.A. Khan, Brain targeted Polysorbate-80 coated PLGA thymoquinone nanoparticles for the treatment of Alzheimer’s disease, with biomechanistic insights, Journal of Drug Delivery Science and Technology, (2020) 102214.
3. M. Yusuf, M. Khan, R.A. Khan, B. Ahmed, Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model, Journal of drug targeting, 21 (2013) 300-311.
4. M. Yusuf, M. Khan, R.A. Khan, I.A. Maghrabi, B. Ahmed, Polysorbate-80-coated, polymeric curcumin nanoparticles for in vivo anti-depressant activity across BBB and envisaged biomolecular mechanism of action through a proposed pharmacophore model, Journal of microencapsulation, 33 (2016) 646-655.
5. M. Yusuf, R.A. Khan, M. Khan, B. Ahmed, Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β-carotene nanoparticles, International journal of nanomedicine, 7 (2012) 4311.
6. S. Srivastava, A.K. Srivastava, Lycopene; chemistry, biosynthesis, metabolism and degradation under various abiotic parameters, Journal of Food Science and Technology, 52 (2015) 41-53.

7. E.N. Story, R.E. Kopec, S.J. Schwartz, G.K. Harris, An update on the health effects of tomato lycopene, Annual review of food science and technology, 1 (2010) 189-210.

8. N. Cardinault, V. Tyssandier, P. Grolier, B.M. Winklhofer-Roob, J. Ribaltu, C. Bouteloup-Demange, E. Rock, P. Borel, Comparison of the postprandial chylomicron carotenoid responses in young and older subjects, European Journal of Nutrition, 42 (2003) 315-323.

9. J. Riedl, J. Linseisen, J.R. Hoffmann, G.n. Wolfram, Some dietary fibers reduce the absorption of carotenoids in women, The Journal of nutrition, 129 (1999) 2170-2176.

10. W. Stahl, H. Sies, Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans, The Journal of nutrition, 122 (1992) 2161-2166.

11. P.R. Trumbo, Are there adverse effects of lycopene exposure?, The Journal of nutrition, 135 (2005) 2060S-2061S.

12. C.T. Kodl, E.R. Seaquist, Cognitive dysfunction and diabetes mellitus, Endocrine reviews, 29 (2008) 494-511.

13. C. National Research Council Committee for the Update of the Guide for the, A. Use of Laboratory, The National Academies Collection: Reports funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals, National Academies Press (US)

14. Copyright © 2011, National Academy of Sciences., Washington (DC), 2011.

15. K. Plaschke, J. Kopitz, M. Siegeln, R. Schliebs, M. Salkovic-Petrisic, P. Riederer, S. Hoyer, Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AβPP-overexpressing mice. Journal of Alzheimer's disease, 19 (2010) 691-704.

16. K. Doi, Y. Morioka, T. Kawano, Artificial cerebrospinal fluid, Google Patents, 2013.

17. R. Porsolt, A. Bertin, M. Jalfre, Behavioral despair in mice: a primary screening test for antidepressants, Archives internationales de pharmacodynamie et de therapie, 229 (1977) 327-336.

18. V.R. Garbarino, M.E. Orr, K.A. Rodriguez, R. Buffenstein, Mechanisms of oxidative stress resistance in the brain: lessons learned from hypoxia tolerant extremophilic vertebrates, Archives of biochemistry and biophysics, 576 (2015) 8-16.

19. M. Rinaldi, M. Caffo, L. Minutoli, H. Marini, R.V. Abbritti, F. Squadrito, V. Trichilo, A. Valenti, V. Barresi, D. Altavilla, ROS and brain gliomas: an overview of potential and innovative therapeutic strategies, International journal of molecular sciences, 17 (2016) 984.

20. S. Raha, B.H. Robinson, Mitochondria, oxygen free radicals, disease and ageing. Trends in biochemical sciences, 25 (2000) 502-508.

21. Q.-G. Zhang, M.D. Laird, D. Han, K. Nguyen, E. Scott, Y. Dong, K.M. Dhandapani, D.W. Brann, Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury, PloS one, 7 (2012).

22. B. Uttara, A.V. Singh, P. Zamboni, R. Mahajan, Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options, Current neuropharmacology, 7 (2009) 65-74.

23. M. Parihar, T. Hemnani, Alzheimer’s disease pathogenesis and therapeutic interventions, Journal of Clinical Neuroscience, 11 (2004) 456-467.

24. V. Pilipenko, J. Pupure, J. Rumaks, U. Beitnere, Z. Dzirkale, R. Skumbins, V. Klusa, ROS and brain gliomas: an overview of potential and innovative therapeutic strategies, International journal of molecular sciences, 17 (2016) 984.

25. S.A. Paiva, R.M. Russell, β-carotene and other carotenoids as antioxidants, Journal of the American college of nutrition, 18 (1999) 426-433.

26. H.R. Matos, V.L. Capelozzi, O.F. Gomes, P. Di Mascio, M.H. Medeiros, Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate, Archives of Biochemistry and Biophysics, 396 (2001) 171-177.

27. Y.N. Engelhard, B. Gazer, E. Paran, Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study, American heart journal, 151 (2006) 100. e106-100. e101.

28. V.K. Selvan, A. Vijayakumar, S. Kumar, G.N. Singh, Lycopene’s effects on health and diseases, Natl Med J, 3 (2011) 2157-2169.

29. M.D.S. Lapiz-Bluhm, C.O. Bondi, J. Doyen, G. Rodriguez, T. Bédard-Arana, D.A. Morilak, Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats, Journal of neuroendocrinology, 20 (2008) 1115-1137.